Importantly, NanoBE demonstrated a significant inhibition of tumor growth compared to Nano/CLDN18.2 or Nano/CD40 alone, highlighting the remarkable synergistic effect of nanoengagers through the crosslinking between macrophages and tumor cells. This evidence concerns the gene CLDN18 and neoplasm.